Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE II OPEN LABEL SINGLE CENTER STUDY OF THE CLINICAL ACTIVITY AND SAFETY OF THE BRAF-V600 INHIBITOR DABRAFENIB (TAFINLAR) IN PREVIOUSLY TREATED PATIENTS WITH HAIRY CELL LEUKEMIA (HCL) CARRYING THE BRAF-V600E MUTATION

Next Previous
Trial Profile

A PHASE II OPEN LABEL SINGLE CENTER STUDY OF THE CLINICAL ACTIVITY AND SAFETY OF THE BRAF-V600 INHIBITOR DABRAFENIB (TAFINLAR) IN PREVIOUSLY TREATED PATIENTS WITH HAIRY CELL LEUKEMIA (HCL) CARRYING THE BRAF-V600E MUTATION

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Mar 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dabrafenib (Primary)
  • Indications Hairy cell leukaemia
  • Focus Therapeutic Use

Most Recent Events

  • 26 Mar 2018 Planned End Date changed from 4 Aug 2017 to 4 Dec 2017.
  • 06 Mar 2018 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top